HRP20191932T1 - Sinteza boronatnih soli i njihove uporabe - Google Patents
Sinteza boronatnih soli i njihove uporabe Download PDFInfo
- Publication number
- HRP20191932T1 HRP20191932T1 HRP20191932TT HRP20191932T HRP20191932T1 HR P20191932 T1 HRP20191932 T1 HR P20191932T1 HR P20191932T T HRP20191932T T HR P20191932TT HR P20191932 T HRP20191932 T HR P20191932T HR P20191932 T1 HRP20191932 T1 HR P20191932T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- compound
- alkyl
- formula
- group
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical class OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 6
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 claims 5
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 239000008139 complexing agent Substances 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
- A01N55/08—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing boron
Claims (13)
1. Spoj formule (I)
ili njegova sol, u kojem:
n je 0 ili 1;
Y1 je O ili N+R5R6;
Y2 je O ili NR10;
R1 i R2 su neovisno izabrani iz grupe koja se sastoji od H, izborno supstituiranog fenila i izborno supstituiranog C1-4 alkila, ili R1 i R2 zajedno s atomima za koje su vezani, formiraju =O;
R3 je izabran iz grupe koja se sastoji od H, izborno supstituiranog fenila i izborno supstituiranog C1-4 alkila, ili R3 i R5, zajedno s atomima za koje su vezani, formiraju heteroaril prsten; ili R3 i R4 zajedno s atomima za koje su vezani, formiraju =O;
R4, R5, R6, i R10 su neovisno izabrani iz grupe koja se sastoji od H, izborno supstituiranog fenila i izborno supstituiranog C1-4 alkila; i
R9 je izabran iz grupe koja se sastoji od izborno supstituiranog C1-C12 alkila, izborno supstituiranog C3-C8 cikloalkila, izborno supstituiranog C2-C12 alkenila, izborno supstituiranog C2-C12 alkinila, izborno supstituiranog arila i izborno supstituiranog heteroarila.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Y1 je O.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Y1 je N+R5R6.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Y2 je O.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što Y2 je NR10.
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 i R2 su oba H.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 i R2 zajedno s atomima za koje su vezani, formiraju =O i gdje R3 i R4 zajedno s atomima za koje su vezani, formiraju =O.
8. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R3 i R4 su oba H.
9. Spoj u skladu s patentnim zahtjevom 1, koji ima strukturu izabranu iz grupe koja se sastoji od:
i
gdje:
M+ je kation izabran iz grupe koja se sastoji od litija, natrija, kalija, kalcija, amonija, trietilamonija i aluminija.
10. Postupak za pripremu spoja formule (I), ili njegove soli, koji sadrži korake:
(a) zaštite hidroksi grupe spoja formule (A):
da bi se formirao spoj formule (B):
(b) reakcije spoja formule (B) sa spojem formule (C):
da bi se formirao spoj formule (D):
(c) uklanjanja zaštitne grupe spoja formule (D) da bi se formirao spoj formule (E):
(d) reakcije spoja formule (E) s kompleksirajućim sredstvom formule (F):
da bi se formirao spoj formule (I):
gdje:
PG je hidroksil zaštitna grupa;
n je 0 ili 1;
Y1 je O ili N+R5R6
Y2 je O ili NR10;
R1 i R2 su neovisno izabrani iz grupe koja se sastoji od H, izborno supstituiranog fenila i izborno supstituiranog C1-4 alkila, ili R1 i R2 zajedno s atomima za koje su vezani, formiraju =O;
R3 je izabran iz grupe koja se sastoji od H, izborno supstituiranog fenila i izborno supstituiranog C1-4alkila ili R1 i R3 zajedno s atomima za koje su vezani formiraju aril ili heteroaril prsten; ili
R3 i R4 zajedno s atomima za koje su vezani, formiraju =O;
R4, R5, R6, i R10 su neovisno izabrani iz grupe koja se sastoji od H, izborno supstituiranog fenila i izborno supstituiranog C1-4 alkila;
R9 je izborno supstituirani C1-C12 alkil, izborno supstituirani C3-C8 cikloalkil, izborno supstituirani C2-C12 alkenil, izborno supstituirani C2-C12 alkinil, izborno supstituirani aril ili izborno supstituirani heteroaril;
R11 je izabran iz grupe koja se sastoji od supstituiranih ili nesupstituiranih varijanti od sljedećih: C1-C12 alkil, C2-C12 alkenil, C2-C12 alkinil, C3-C12 cikloalkil, C3-C12 cikloalkenil, C3-C12 cikloalkinil, C3-C12 heterociklil, aril, heteroaril, arilalkil, heteroarilalkil i (cikloalkil)alkil, i
X je izabran iz grupe koja se sastoji od supstituiranih ili nesupstituiranih varijanti od sljedećih: C1-C4 alkil, C2-C4 alkenil i C2-C4 alkinil; i
R12 je izabran iz grupe koja se sastoji od supstituiranih ili nesupstituiranih varijanti od sljedećih: C1-C12 alkil, C2-C12 alkenil, C2-C12 alkinil, C3-C12 cikloalkil, C3-C12 cikloalkenil, C3-C12 cikloalkinil, C3-C12 heterociklil, aril, heteroaril, arilalkil, heteroarilalkil i (cikloalkil)alkil.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što R9 je izborno supstituirani C1-C12 alkil.
12. Postupak za pripremu spoja formule (I), ili njegove soli, koji sadrži korake: reakcije spoja formule (E):
s kompleksirajućim sredstvom formule (F):
da bi se formirao spoj formule (I):
gdje
n je 0 ili 1,
Y1 je O ili N+R5R6
Y2 = O ili NR10,
R1, R2, R3, R4, R5, R6, i R10 su neovisno izabrani iz grupe koja se sastoji od H, izborno supstituiranog fenila i izborno supstituiranog C1-4 alkila; ili
pri čemu neovisno dva geminalna R1, R2, R3, R4 zajedno s atomima za koje su vezani, formiraju =O; i
pri čemu R9 je izborno supstituirani C1-C12 alkil, izborno supstituirani C3-C8 cikloalkil, izborno supstituirani C2-C12 alkenil, izborno supstituirani C2-C12 alkinil, izborno supstituirani aril ili izborno supstituirani heteroaril.
13. Postupak u skladu s patentnim zahtjevom 12, naznačen time što R1 i R2 zajedno s atomima za koje su vezani, formiraju =O i naznačen time da R3 i R4 zajedno s atomima za koje su vezani, formiraju =O.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988690P | 2014-05-05 | 2014-05-05 | |
| PCT/US2015/028613 WO2015171430A1 (en) | 2014-05-05 | 2015-04-30 | Synthesis of boronate salts and uses thereof |
| EP15788682.1A EP3140310B1 (en) | 2014-05-05 | 2015-04-30 | Synthesis of boronate salts and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191932T1 true HRP20191932T1 (hr) | 2020-01-24 |
Family
ID=54392864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191932TT HRP20191932T1 (hr) | 2014-05-05 | 2019-10-23 | Sinteza boronatnih soli i njihove uporabe |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10385074B2 (hr) |
| EP (3) | EP3140310B1 (hr) |
| CY (1) | CY1122222T1 (hr) |
| DK (1) | DK3140310T3 (hr) |
| ES (1) | ES2750805T3 (hr) |
| FI (1) | FI3604316T3 (hr) |
| HR (1) | HRP20191932T1 (hr) |
| HU (1) | HUE046836T2 (hr) |
| LT (2) | LT3604316T (hr) |
| PL (2) | PL3604316T3 (hr) |
| PT (1) | PT3140310T (hr) |
| RS (1) | RS59488B1 (hr) |
| SI (1) | SI3140310T1 (hr) |
| WO (1) | WO2015171430A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2603514T (pt) | 2010-08-10 | 2018-11-09 | Rempex Pharmaceuticals Inc | Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas |
| CA2894891A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CA2947041A1 (en) | 2014-05-19 | 2015-11-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3882252A1 (en) | 2014-06-11 | 2021-09-22 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP3164406A4 (en) | 2014-07-01 | 2018-04-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| EP3233869B1 (en) | 2014-12-19 | 2019-09-25 | Rempex Pharmaceuticals, Inc. | Apparatus and continuous flow process for production of boronic acid derivatives |
| US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP3347008B1 (en) | 2015-09-11 | 2022-03-09 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2018005662A1 (en) | 2016-06-30 | 2018-01-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2018027062A1 (en) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| JOP20190188A1 (ar) | 2017-02-01 | 2019-08-01 | Rempex Pharmaceuticals Inc | جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك |
| WO2018218154A1 (en) | 2017-05-26 | 2018-11-29 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2019075084A1 (en) | 2017-10-11 | 2019-04-18 | Qpex Biopharma, Inc. | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF |
| CA3080763A1 (en) * | 2017-11-01 | 2019-05-09 | Melinta Therapeutics, Inc. | Synthesis of boronate ester derivatives and uses thereof |
| CN111039965B (zh) * | 2018-10-12 | 2020-12-01 | 新发药业有限公司 | 一种法硼巴坦的简便制备方法 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4194047A (en) | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
| US4260543A (en) | 1978-07-03 | 1981-04-07 | Merck & Co., Inc. | Crystalline N-formimidoyl thienamycin |
| US4409214A (en) | 1979-11-19 | 1983-10-11 | Fujisawa Pharmaceutical, Co., Ltd. | 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof |
| FR2573070B1 (fr) | 1984-11-13 | 1987-01-30 | Rhone Poulenc Sante | Procede de preparation de composes carbonyles |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| US4822786A (en) | 1986-07-01 | 1989-04-18 | Kaken Pharmaceutical Co., Ltd. | Cephalosporin compounds, and antibacterial agents |
| ZA893284B (en) | 1988-05-04 | 1990-03-28 | Igen Inc | Peptide analogs and their use as haptens to elicit catalytic antibodies |
| US5442100A (en) | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
| US5888998A (en) | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
| JP2002504122A (ja) | 1997-06-13 | 2002-02-05 | ノースウエスタン ユニバーシティー | ベータラクタマーゼ阻害剤及びその使用方法 |
| US6184363B1 (en) | 1997-06-13 | 2001-02-06 | Northwestern University | Inhibitors of β-lactamases and uses therefor |
| WO2000035904A1 (en) | 1998-12-16 | 2000-06-22 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| WO2000035905A1 (en) | 1998-12-16 | 2000-06-22 | Northwestern University | INHIBITORS OF β-LACTAMASES AND USES THEREFOR |
| CA2385737A1 (en) | 1999-09-25 | 2001-04-05 | Howard Marshall | Piperazine derivatives as 5-ht1b antagonists |
| JP2003513890A (ja) | 1999-10-28 | 2003-04-15 | メルク エンド カムパニー インコーポレーテッド | 新規なコハク酸系メタロ−β−ラクタマーゼ阻害薬およびそれの細菌感染治療での使用 |
| AU2001292732A1 (en) | 2000-09-12 | 2002-03-26 | Larry C. Blasczcak | Beta-lactam analogs and uses therefor |
| DE60111757T2 (de) | 2000-09-14 | 2006-04-27 | Pantherix Ltd. | 3-(Heteroarylacetamido)-2-oxoazetidin-1-sulfonsäure-derivate als antibakterielle Mittel |
| AU2002243508A1 (en) | 2001-01-10 | 2002-07-24 | Bristol-Myers Squibb Company Patent Department | Alpha-aminoboronic acids prepared by novel synthetic methods |
| DE10118698A1 (de) | 2001-04-17 | 2002-11-07 | Jerini Ag | Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| JP2003229277A (ja) | 2002-02-04 | 2003-08-15 | Matsushita Electric Ind Co Ltd | 発光素子材料およびそれを用いた発光素子並びに装置 |
| AUPS065102A0 (en) | 2002-02-20 | 2002-03-14 | Unisearch Limited | Fluorous acetalation |
| AU2003261974A1 (en) | 2002-09-11 | 2004-04-30 | Kureha Chemical Industry Company, Limited | Amine compounds and use thereof |
| KR101002822B1 (ko) | 2002-10-30 | 2010-12-21 | 스미또모 가가꾸 가부시키가이샤 | 고분자 화합물 및 이를 이용한 고분자 발광 소자 |
| US7439253B2 (en) | 2002-12-06 | 2008-10-21 | Novexel | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| CA2511178A1 (en) | 2002-12-20 | 2004-07-15 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| JP4233365B2 (ja) | 2003-03-25 | 2009-03-04 | 三井化学株式会社 | アザジオール錯体化合物、及び該化合物を用いる光記録媒体 |
| US7842941B2 (en) | 2003-10-06 | 2010-11-30 | Sumitomo Chemical Company, Limited | Aromatic compound |
| WO2005035532A1 (en) | 2003-10-10 | 2005-04-21 | Pfizer Products Inc. | Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors |
| TW200600494A (en) | 2004-03-08 | 2006-01-01 | Chugai Pharmaceutical Co Ltd | Bisphenyl compounds useful as vitamin d3 receptor agonists |
| US20060019116A1 (en) | 2004-07-22 | 2006-01-26 | Eastman Kodak Company | White electroluminescent device with anthracene derivative host |
| TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| US20060178357A1 (en) | 2005-02-10 | 2006-08-10 | Buynak John D | Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases |
| JP5038912B2 (ja) | 2005-02-16 | 2012-10-03 | アナコール ファーマシューティカルズ，インコーポレイテッド | ホウ素含有小分子 |
| TWI353981B (en) | 2005-02-22 | 2011-12-11 | Teva Pharma | Preparation of rosuvastatin |
| US9184428B2 (en) | 2005-03-15 | 2015-11-10 | Uchicago Argonne Llc | Non-aqueous electrolytes for lithium ion batteries |
| TW200734311A (en) | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
| KR101403164B1 (ko) | 2005-12-07 | 2014-06-03 | 바실리어 파마슈티카 아게 | 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합 |
| PT2719388T (pt) | 2006-02-16 | 2019-06-11 | Anacor Pharmaceuticals Inc | Moléculas pequenas que contêm boro como agentes antiinflamatórios |
| AU2007300531A1 (en) | 2006-09-27 | 2008-04-03 | Merck Sharp & Dohme Corp. | Novel inhibitors of beta-lactamase |
| KR101320718B1 (ko) | 2007-03-23 | 2013-10-21 | 바실리어 파마슈티카 아게 | 세균 감염 치료용 조합 약제 |
| GB0719366D0 (en) | 2007-10-03 | 2007-11-14 | Smithkline Beecham Corp | Compounds |
| JP2011503181A (ja) | 2007-11-13 | 2011-01-27 | プロテズ・ファーマシューティカルズ・インコーポレイテッド | ベータ−ラクタマーゼ阻害剤 |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| RS53862B1 (en) | 2008-01-18 | 2015-08-31 | Merck Sharp & Dohme Corp. | INHIBITOR BETA-LACTAMASE |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| EP2285384A4 (en) | 2008-05-12 | 2012-04-25 | Anacor Pharmaceuticals Inc | BORN SMALL MOLECULES |
| US20110124634A1 (en) | 2008-05-13 | 2011-05-26 | Poniard Pharmaceuticals, Inc. | Bioactive compounds for treatment of cancer and neurodegenerative diseases |
| US20120046242A1 (en) | 2008-12-24 | 2012-02-23 | Massachusetts Institute Of Technology | Molecular activators of the wnt/beta-catenin pathway |
| WO2010097675A1 (en) | 2009-02-27 | 2010-09-02 | Dhanuka Laboratories Ltd. | An improved preparation process for cefpodoxime proxetil |
| AR076667A1 (es) | 2009-05-12 | 2011-06-29 | Novartis Int Pharm Ltd | Inhibidores de beta-lactamasa |
| US20120238576A1 (en) | 2009-06-08 | 2012-09-20 | California Capital Equity, Llc | Triazine Derivatives and their Therapeutical Applications |
| BR112012001987A2 (pt) | 2009-07-28 | 2015-09-01 | Anacor Pharmaceuticals Inc | Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase. |
| CA2828114A1 (en) | 2010-02-26 | 2011-09-01 | Gary Igor DMITRIENKO | Cephalosporin derivatives useful as .beta.-lactamase inhibitors and compositions and methods of use thereof |
| KR20130036228A (ko) | 2010-03-31 | 2013-04-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 1-아미노-2-사이클로프로필에틸보론산의 유도체 |
| US20110288063A1 (en) | 2010-05-19 | 2011-11-24 | Naeja Pharmaceutical Inc. | Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors |
| PT2603514T (pt) | 2010-08-10 | 2018-11-09 | Rempex Pharmaceuticals Inc | Derivados cíclicos de éster de ácido borónico e suas utilizações terapêuticas |
| ES2568680T3 (es) | 2010-10-26 | 2016-05-03 | Mars, Incorporated | Boratos como inhibidores de arginasa |
| WO2012067664A1 (en) | 2010-11-18 | 2012-05-24 | Glaxo Group Limited | Compounds |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| EP2508506A1 (en) | 2011-04-08 | 2012-10-10 | LEK Pharmaceuticals d.d. | Preparation of sitagliptin intermediates |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| WO2013056163A1 (en) | 2011-10-14 | 2013-04-18 | The Regents Of The University Of California | Beta-lactamase inhibitors |
| BR112014015363A8 (pt) | 2011-12-22 | 2017-06-13 | Ares Trading Sa | derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos |
| US20150018311A1 (en) | 2012-01-09 | 2015-01-15 | University of Tromsø | Therapeutic boron-containing compounds |
| EP2615080A1 (en) | 2012-01-12 | 2013-07-17 | LEK Pharmaceuticals d.d. | Preparation of Optically Pure ß-Amino Acid Type Active Pharmaceutical Ingredients and Intermediates thereof |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| PT2928898T (pt) | 2012-12-07 | 2021-07-05 | Venatorx Pharmaceuticals Inc | Inibidores de beta-lactamase |
| CA2894891A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CA2894892A1 (en) | 2013-01-04 | 2014-07-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US8999885B2 (en) | 2013-01-09 | 2015-04-07 | General Electric Company | Methods of activating charcoal resulting from biomass gasification |
| EP2943204B1 (en) | 2013-01-10 | 2019-03-13 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
| WO2014151958A1 (en) | 2013-03-14 | 2014-09-25 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| CA2947041A1 (en) | 2014-05-19 | 2015-11-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP3164406A4 (en) | 2014-07-01 | 2018-04-04 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016065282A1 (en) | 2014-10-24 | 2016-04-28 | The Regents Of The University Of Michigan | Nasal formulation, nasal kit, and method for enhancing nasal nitric oxide (no) levels |
| ES2942329T3 (es) | 2015-04-24 | 2023-05-31 | Melinta Therapeutics Inc | Régimen de dosificación de vaborbactam y meropenem para el tratamiento de infecciones bacterianas en sujetos con función renal reducida |
-
2015
- 2015-04-30 DK DK15788682.1T patent/DK3140310T3/da active
- 2015-04-30 RS RS20191368A patent/RS59488B1/sr unknown
- 2015-04-30 PL PL19186092.3T patent/PL3604316T3/pl unknown
- 2015-04-30 WO PCT/US2015/028613 patent/WO2015171430A1/en active Application Filing
- 2015-04-30 EP EP15788682.1A patent/EP3140310B1/en active Active
- 2015-04-30 EP EP19186092.3A patent/EP3604316B1/en active Active
- 2015-04-30 US US15/305,954 patent/US10385074B2/en active Active
- 2015-04-30 LT LTEP19186092.3T patent/LT3604316T/lt unknown
- 2015-04-30 SI SI201530973T patent/SI3140310T1/sl unknown
- 2015-04-30 EP EP23214076.4A patent/EP4356736A2/en active Pending
- 2015-04-30 FI FIEP19186092.3T patent/FI3604316T3/fi active
- 2015-04-30 LT LT15788682T patent/LT3140310T/lt unknown
- 2015-04-30 PL PL15788682T patent/PL3140310T3/pl unknown
- 2015-04-30 PT PT157886821T patent/PT3140310T/pt unknown
- 2015-04-30 HU HUE15788682A patent/HUE046836T2/hu unknown
- 2015-04-30 ES ES15788682T patent/ES2750805T3/es active Active
-
2019
- 2019-08-02 US US16/530,625 patent/US10669292B2/en active Active
- 2019-10-23 HR HRP20191932TT patent/HRP20191932T1/hr unknown
- 2019-11-01 CY CY20191101140T patent/CY1122222T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3604316T3 (pl) | 2024-04-29 |
| SI3140310T1 (sl) | 2020-01-31 |
| FI3604316T3 (fi) | 2024-02-29 |
| DK3140310T3 (da) | 2019-10-21 |
| EP3140310B1 (en) | 2019-08-07 |
| US20170057979A1 (en) | 2017-03-02 |
| EP3140310A4 (en) | 2017-12-13 |
| CY1122222T1 (el) | 2020-11-25 |
| EP4356736A2 (en) | 2024-04-24 |
| PL3140310T3 (pl) | 2020-01-31 |
| LT3140310T (lt) | 2019-11-25 |
| EP3140310A1 (en) | 2017-03-15 |
| EP3604316B1 (en) | 2023-12-06 |
| US10385074B2 (en) | 2019-08-20 |
| RS59488B1 (sr) | 2019-12-31 |
| US20200031851A1 (en) | 2020-01-30 |
| EP3604316A1 (en) | 2020-02-05 |
| US10669292B2 (en) | 2020-06-02 |
| PT3140310T (pt) | 2019-11-18 |
| LT3604316T (lt) | 2024-02-26 |
| HUE046836T2 (hu) | 2020-03-30 |
| ES2750805T3 (es) | 2020-03-27 |
| WO2015171430A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191932T1 (hr) | Sinteza boronatnih soli i njihove uporabe | |
| RS54264B1 (en) | 4-ARYL-N-PHENYL-1,3,5-TRIAZINE-2-AMINES CONTAINING SULPHOXIMINE GROUP | |
| HRP20180067T1 (hr) | Inhibitori histon demetilaze | |
| EA201791584A1 (ru) | Агрохимическая композиция | |
| BR112018005307A2 (pt) | aditivo para conferir baixo acúmulo de calor a um componente de borracha | |
| EA201591695A1 (ru) | Экологически безопасные постоянные четвертичные полиамины и их использование в качестве стабилизаторов глин и способы их получения и применения | |
| EA201390884A1 (ru) | Азабензимидазолы в качестве противовирусных средств в отношении респираторного синцитиального вируса | |
| HRP20161092T1 (hr) | Cdk inhibitori | |
| RS53244B (en) | 1`-SUBSTITUTED-CARB-NUCLEOSIDE PROTECTION FOR ANTI-VIRUS TREATMENT | |
| RS53830B1 (en) | INDASOLS SUBSTITUTED BY OXAZOLE AS PI3-KINASE INHIBITORS | |
| RS54761B1 (sr) | Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi | |
| MY182568A (en) | Quaternary ammonium compounds and their use as fuel or lubricant additives | |
| HRP20211922T1 (hr) | Postupci i intermedijeri za pripravu jak inhibitora | |
| RS54048B1 (en) | PARASITICIDE COMPOUNDS OF DIHYDROISOXAZOLE | |
| PE20151764A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| RS54480B1 (en) | IMIDAZOPYRIDASINE AS ACT KINASE INHIBITORS | |
| RS54730B1 (sr) | Inhibitori beta sekretaze | |
| MY194307A (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| EA201891870A1 (ru) | Производные иминотиадиазинандиоксида в качестве ингибиторов плазмепсина v | |
| ES2526902T3 (es) | Procesos de producción de inhibidores de la girasa y topoisomerasa IV | |
| BR112016002063A2 (pt) | composto de tetrazolinona e uso do mesmo | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| HRP20220636T1 (hr) | Spojevi korisni kao inhibitori ripk1 | |
| MA39715A (fr) | Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation | |
| BR112014031741A2 (pt) | composto de amida e uso do mesmo para controle de peste |